Literature DB >> 18656457

uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK.

William M Armstead1, Douglas B Cines, Khalil Bdeir, Irina Kulikovskaya, Sherman C Stein, Abd Al-Roof Higazi.   

Abstract

We have previously observed that soluble urokinase plasminogen activator receptor (suPAR) prevents impairment of cerebrovasodilation induced by hypercapnia and hypotension after hypoxia/ischemia (H/I) in the newborn pig. In this study, we investigated the role of low-density lipoprotein-related protein (LRP) receptor and the ERK isoform of mitogen activated protein kinase (MAPK) in uPA-mediated impairment of vasodilation after H/I in piglets equipped with a closed cranial window. CSF uPA increased from 9+/-2 to 52+/-8 and 140+/-21 ng/ml at 1 and 4 h after H/I, respectively. The LRP antagonist receptor associated protein (RAP) and anti-LRP antibody blunted the increase in CSF uPA at 1 h (17+/-2 ng/ml) but not 4 h post insult. uPA detectable in sham-treated cortex by immunohistochemistry was markedly elevated 4 h after H/I. Phosphorylation (activation) of CSF ERK MAPK was detected at 1 and 4 h post H/I and blocked by RAP. Exogenous uPA administered at 4 h post H/I further stimulated ERK MAPK phosphorylation, which was blocked by RAP. Pre-treatment of piglets with RAP, anti-LRP, and suPAR completely prevented, and the ERK MAPK antagonist U 0126 partially prevented, impaired responses to hypotension and hypercapnia post H/I, but none of these antagonists affected the response to isoproterenol. These data indicate that uPA is upregulated after H/I through an LRP-dependent process and that the released uPA impairs hypercapnic and hypotensive dilation through an LRP- and ERK MAPK dependent pathway. These data suggest that modulation of uPA upregulation and/or uPA-mediated signal transduction may preserve cerebrohemodynamic control after hypoxia/ischemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18656457      PMCID: PMC2572778          DOI: 10.1016/j.brainres.2008.06.115

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  32 in total

1.  Symptomatic ischemic stroke in full-term neonates : role of acquired and genetic prothrombotic risk factors.

Authors:  G Günther; R Junker; R Sträter; R Schobess; K Kurnik; C Heller; A Kosch; U Nowak-Göttl
Journal:  Stroke       Date:  2000-10       Impact factor: 7.914

2.  c-Jun N-terminal kinase (JNK) and JNK interacting protein response in rat brain after transient middle cerebral artery occlusion.

Authors:  T Hayashi; K Sakai; C Sasaki; W R Zhang; H Warita; K Abe
Journal:  Neurosci Lett       Date:  2000-04-28       Impact factor: 3.046

3.  Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo.

Authors:  A Haj-Yehia; T Nassar; B S Sachais; A Kuo; K Bdeir; A B Al-Mehdi; A Mazar; D B Cines; A A Higazi
Journal:  FASEB J       Date:  2000-07       Impact factor: 5.191

4.  Alteration of MAP kinase pathways after transient forebrain ischemia.

Authors:  B R Hu; C L Liu; D J Park
Journal:  J Cereb Blood Flow Metab       Date:  2000-07       Impact factor: 6.200

5.  Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig.

Authors:  William M Armstead; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Stroke       Date:  2005-09-01       Impact factor: 7.914

6.  MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia.

Authors:  A Alessandrini; S Namura; M A Moskowitz; J V Bonventre
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

7.  The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.

Authors:  O Nicole; F Docagne; C Ali; I Margaill; P Carmeliet; E T MacKenzie; D Vivien; A Buisson
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

8.  Cerebral sinovenous thrombosis in children.

Authors:  G deVeber; M Andrew; C Adams; B Bjornson; F Booth; D J Buckley; C S Camfield; M David; P Humphreys; P Langevin; E A MacDonald; J Gillett; B Meaney; M Shevell; D B Sinclair; J Yager
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

9.  Urokinase mediates fibrinolysis in the pulmonary microvasculature.

Authors:  K Bdeir; J C Murciano; J Tomaszewski; L Koniaris; J Martinez; D B Cines; V R Muzykantov; A A Higazi
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

10.  Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion.

Authors:  N Hosomi; J Lucero; J H Heo; J A Koziol; B R Copeland; G J del Zoppo
Journal:  Stroke       Date:  2001-06       Impact factor: 7.914

View more
  19 in total

1.  Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK.

Authors:  William M Armstead; John Riley; J Willis Kiessling; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-06-10       Impact factor: 3.619

2.  Combination therapy with glucagon and a novel plasminogen activator inhibitor-1-derived peptide enhances protection against impaired cerebrovasodilation during hypotension after traumatic brain injury through inhibition of ERK and JNK MAPK.

Authors:  William M Armstead; John Riley; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Neurol Res       Date:  2012-05-30       Impact factor: 2.448

3.  tPA contributes to impairment of ATP and Ca sensitive K channel mediated cerebrovasodilation after hypoxia/ischemia through upregulation of ERK MAPK.

Authors:  William M Armstead; John Riley; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Brain Res       Date:  2010-12-20       Impact factor: 3.252

4.  Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig.

Authors:  William M Armstead; Kumkum Ganguly; John Riley; J Willis Kiessling; Douglas B Cines; Abd A R Higazi; Sergei Zaitsev; Vladimir R Muzykantov
Journal:  Pediatr Crit Care Med       Date:  2011-11       Impact factor: 3.624

5.  tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK.

Authors:  William M Armstead; J Willis Kiessling; John Riley; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Neurol Res       Date:  2011-09       Impact factor: 2.448

6.  PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.

Authors:  William M Armstead; John Riley; J Willis Kiessling; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-30       Impact factor: 4.733

7.  Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice.

Authors:  Taher Nassar; Serge Yarovoi; Rami Abu Fanne; Otailah Waked; Timothy C Allen; Steven Idell; Douglas B Cines; Abd Al-Roof Higazi
Journal:  Am J Respir Cell Mol Biol       Date:  2011-05-26       Impact factor: 6.914

Review 8.  Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.

Authors:  William M Armstead; Kumkum Ganguly; J W Kiessling; John Riley; Xiao-Han Chen; Douglas H Smith; Sherman C Stein; Abd A R Higazi; Douglas B Cines; Khalil Bdeir; Sergei Zaitsev; Vladimir R Muzykantov
Journal:  J Neurochem       Date:  2010-04       Impact factor: 5.372

9.  Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation.

Authors:  William M Armstead; Kumkum Ganguly; John W Kiessling; Xiao-Han Chen; Douglas H Smith; Abd A R Higazi; Douglas B Cines; Khalil Bdeir; Sergei Zaitsev; Vladimir R Muzykantov
Journal:  J Cereb Blood Flow Metab       Date:  2009-05-13       Impact factor: 6.200

10.  tPA-S(481)A prevents impairment of cerebrovascular autoregulation by endogenous tPA after traumatic brain injury by upregulating p38 MAPK and inhibiting ET-1.

Authors:  William M Armstead; Leif-Erik Bohman; John Riley; Serge Yarovoi; Abd Al-Roof Higazi; Douglas B Cines
Journal:  J Neurotrauma       Date:  2013-08-24       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.